2020/08/03 ALA -1000 Receive notice of patent allowance from the IP Australia. Post author:alarpharm Post published:25 . 8 . 2020 Post category:Media releases You Might Also Like 2021/10/28 Alar Pharmaceuticals Inc. Completes Successful End-of-Phase 2 Meeting with US FDA for ALA-1000 for the Treatment of Opioid Use Disorder 28 . 10 . 2021 2020/08/21 Alar Pharmaceuticals Inc. Completes Pre-IND Meeting with US FDA for ALA-3000 24 . 8 . 2020 2022/01/13 Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000 14 . 1 . 2022 2021/04/30 ALA-1000 was granted by Intellectual Property Office of New Zealand.Patent No. 750367. 3 . 5 . 2021 2021/04/13 -Alar Pharmaceuticals Inc., participates in American Society of Addiction Medicine (ASAM) Virtual 2021, the nation’s largest and premier conference on addiction medicine, which will hold this year between 22 – 24 April. 13 . 4 . 2021
2021/10/28 Alar Pharmaceuticals Inc. Completes Successful End-of-Phase 2 Meeting with US FDA for ALA-1000 for the Treatment of Opioid Use Disorder 28 . 10 . 2021
2020/08/21 Alar Pharmaceuticals Inc. Completes Pre-IND Meeting with US FDA for ALA-3000 24 . 8 . 2020
2022/01/13 Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000 14 . 1 . 2022
2021/04/30 ALA-1000 was granted by Intellectual Property Office of New Zealand.Patent No. 750367. 3 . 5 . 2021
2021/04/13 -Alar Pharmaceuticals Inc., participates in American Society of Addiction Medicine (ASAM) Virtual 2021, the nation’s largest and premier conference on addiction medicine, which will hold this year between 22 – 24 April. 13 . 4 . 2021
